2,3,6,7-Tetrachloroquinoxaline - CAS 25983-14-6
Catalog: |
BB019097 |
Product Name: |
2,3,6,7-Tetrachloroquinoxaline |
CAS: |
25983-14-6 |
Synonyms: |
2,3,6,7-tetrachloroquinoxaline |
IUPAC Name: | 2,3,6,7-tetrachloroquinoxaline |
Description: | 2,3,6,7-Tetrachloroquinoxaline (CAS# 25983-14-6) is a useful research chemical. |
Molecular Weight: | 267.93 |
Molecular Formula: | C8H2Cl4N2 |
Canonical SMILES: | C1=C2C(=CC(=C1Cl)Cl)N=C(C(=N2)Cl)Cl |
InChI: | InChI=1S/C8H2Cl4N2/c9-3-1-5-6(2-4(3)10)14-8(12)7(11)13-5/h1-2H |
InChI Key: | GQWLQHHUPKCOJH-UHFFFAOYSA-N |
Boiling Point: | 319.8 °C at 760 mmHg |
Density: | 1.697 g/cm3 |
Appearance: | Tan powder |
MDL: | MFCD00012333 |
LogP: | 4.24340 |
GHS Hazard Statement: | H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]; H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]; H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]; H335 (100%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure; Respiratory tract irritation] |
Precautionary Statement: | P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 |
Signal Word: | Warning |
Publication Number | Title | Priority Date |
KR-20180106597-A | Novel [1,2,4]triazolo[4,3-a]quinoxaline amino phenyl derivatives or pharmaceutically acceptable salts thereof, preparation method therof and pharmaceutical composition for use in preventing or treating bromodomain extra-terminal(BET) protein activity related diseases containing the same as an active ingredient | 20170321 |
KR-102070265-B1 | Novel [1,2,4]Triazolo[4,3-a]quinoxaline derivatives, preparation method therof, and pharmaceutical composition for use in preventing or treating BET protein related diseases containing the same as an active ingredient | 20170126 |
KR-20180089298-A | Novel [1,2,4]Triazolo[4,3-a]quinoxaline derivatives, preparation method therof, and pharmaceutical composition for use in preventing or treating BET protein related diseases containing the same as an active ingredient | 20170126 |
US-2020039984-A1 | Novel [1,2,4]Triazolo[4,3-a]Quinoxaline Derivative, Method For Preparing Same, And Pharmaceutical Composition For Preventing Or Treating BET Protein-Related Diseases, Containing Same As Active Ingredient | 20170126 |
WO-2018139876-A1 | Novel [1,2,4]triazolo[4, 3-a]quinoxaline derivative, method for preparing same, and pharmaceutical composition for preventing or treating bet protein-related diseases, containing same as active ingredient | 20170126 |
Complexity: | 194 |
Compound Is Canonicalized: | Yes |
Covalently-Bonded Unit Count: | 1 |
Defined Atom Stereocenter Count: | 0 |
Defined Bond Stereocenter Count: | 0 |
Exact Mass: | 267.894259 |
Formal Charge: | 0 |
Heavy Atom Count: | 14 |
Hydrogen Bond Acceptor Count: | 2 |
Hydrogen Bond Donor Count: | 0 |
Isotope Atom Count: | 0 |
Monoisotopic Mass: | 265.897209 |
Rotatable Bond Count: | 0 |
Topological Polar Surface Area: | 25.8 |
Undefined Atom Stereocenter Count: | 0 |
Undefined Bond Stereocenter Count: | 0 |
XLogP3: | 4.4 |
Online Inquiry
Customer Support
Customer Centered
Related Functional Groups
Quinoxalines
Customers Also Viewed
INDUSTRY LEADERS TRUST OUR PRODUCTS